A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Target Recruit Count
- 33
- Registration Number
- NCT06608329
- Locations
- 🇨🇳
Hangzhou First People's Hospital, Hangzhou, Zhejiang, China
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects
Phase 1
Not yet recruiting
- Conditions
- Healthy Adult SubjectOverweight Subject
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Target Recruit Count
- 30
- Registration Number
- NCT06601517
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 10
- Registration Number
- NCT06576401
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects
Phase 1
Not yet recruiting
- Conditions
- Healthy Adult Subject
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Target Recruit Count
- 40
- Registration Number
- NCT06562088
- Locations
- 🇨🇳
The second hospital of anhui medical university, Hefei, Anhui, China
HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects
Phase 1
Not yet recruiting
- Conditions
- Glucagon-Like Peptide-1 Receptor Agonists
- Interventions
- Drug: HDM1002 100 mg QD 12weeksDevice: PlaceboDrug: HDM1002 200 mg QD 12weeksDrug: HDM1002 400 mg QD 12weeks，Q 2W for titrationDrug: HDM1002 400 mg QD 12weeks，Q 3W for titration
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Target Recruit Count
- 72
- Registration Number
- NCT06520540
- Locations
- 🇨🇳
HDM1002, Shanghai, Shanghai, China
Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
Phase 2
Not yet recruiting
- Conditions
- Overweight and Obesity
- Interventions
- Drug: HDM1002 100 mg QDDrug: HDM1002 200 mg QD 12weeksDrug: HDM1002 400 mg QD 12weeksDrug: Placebo
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Target Recruit Count
- 180
- Registration Number
- NCT06500299
To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Phase 2
Not yet recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: HDM1002 100 mgDrug: HDM1002 200 mg BIDDrug: HDM1002 200 mgDrug: HDM1002 400 mgDrug: HDM1002 50 mgDrug: Placebo
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-07-01
- Target Recruit Count
- 318
- Registration Number
- NCT06481085
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, China
🇨🇳The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China
🇨🇳Suzhou Municipal Hospital, Suzhou, China
A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants
Phase 3
Completed
- Conditions
- Kidney DiseasesKidney InjuryKidney Failure
- Interventions
- Drug: MB-102 DMIDDrug: MB-102 OMIDDevice: MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2024-01-02
- Target Recruit Count
- 121
- Registration Number
- NCT05943977
- Locations
- 🇨🇳
Suzhou Municipal Hospital, Suzhou, Jiangsu, China
🇨🇳Affiliated hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
Phase 3
Recruiting
- Conditions
- Epithelial Ovarian CancerPeritoneal CancerFallopian Tube Cancer
- Interventions
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2022-11-21
- Target Recruit Count
- 35
- Registration Number
- NCT05622890
- Locations
- 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
© Copyright 2025. All Rights Reserved by MedPath